Literature DB >> 19279411

Severity of inflammation as a predictor of colectomy in patients with chronic ulcerative colitis.

Marco M Hefti1, David B Chessin, Noam H Harpaz, Randolph M Steinhagen, Thomas A Ullman.   

Abstract

PURPOSE: We evaluated a large cohort of patients with longstanding ulcerative colitis in a colonoscopic surveillance program to determine predictors of colectomy.
METHODS: We queried a retrospective database of patients who had symptoms of ulcerative colitis for seven years or more. Histologic inflammation in biopsies was graded on a validated four-point scale: absent, mild, moderate, severe. We performed a multivariate analysis of the inflammation scores and other variables to determine predictive factors for colectomy. Patients who underwent colectomy for neoplasia were censored at the time of surgery; those who did not undergo colectomy were censored at the time of last contact.
RESULTS: A total of 561 patients were evaluated, with a median follow-up of 21.4 years since disease onset. A total of 97 patients (17.3 percent) underwent surgery; 25 (4.5 percent) for reasons other than dysplasia. These 25 constitute events for this analysis. For univariate analysis, mean inflammation (P < 0.001) and steroid use (P = 0.01) were predictors of colectomy. For multivariable proportional hazards analysis, mean inflammation (P < 0.001) and steroid use (P = 0.03) were predictors of colectomy, whereas salicylate use (P = 0.007) was protective.
CONCLUSIONS: Higher median inflammation scores and corticosteroid use were predictors of colectomy in this patient population. The overall rate of colectomy during a long period of follow-up was low (<1 percent per year).

Entities:  

Mesh:

Year:  2009        PMID: 19279411      PMCID: PMC2753491          DOI: 10.1007/DCR.0b013e31819ad456

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  17 in total

1.  Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index.

Authors:  Mitsuru Seo; Mitsuo Okada; Tsuneyoshi Yao; Hiroaki Matake; Kazuhiro Maeda
Journal:  J Gastroenterol       Date:  2002-01       Impact factor: 7.527

2.  An index of disease activity in patients with ulcerative colitis.

Authors:  M Seo; M Okada; T Yao; M Ueki; S Arima; M Okumura
Journal:  Am J Gastroenterol       Date:  1992-08       Impact factor: 10.864

3.  Genetic markers may predict disease behavior in patients with ulcerative colitis.

Authors:  M Roussomoustakaki; J Satsangi; K Welsh; E Louis; G Fanning; S Targan; C Landers; D P Jewell
Journal:  Gastroenterology       Date:  1997-06       Impact factor: 22.682

4.  Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification.

Authors:  M Seo; M Okada; T Yao; N Okabe; K Maeda; K Oh
Journal:  Am J Gastroenterol       Date:  1995-10       Impact factor: 10.864

5.  Predicting outcome in severe ulcerative colitis.

Authors:  S P Travis; J M Farrant; C Ricketts; D J Nolan; N M Mortensen; M G Kettlewell; D P Jewell
Journal:  Gut       Date:  1996-06       Impact factor: 23.059

6.  [Predictors of colectomy in patients with ulcerative colitis. A cohort analysis of 184 cases].

Authors:  Arsenio Choquet; Jesús K Yamamoto-Furusho; Edgardo Reyes; Takeshi Takahashi-Monroy; Florencia Vargas-Vorácková; Luis Uscanga
Journal:  Rev Invest Clin       Date:  2004 Jan-Feb       Impact factor: 1.451

Review 7.  C-reactive protein as a marker for inflammatory bowel disease.

Authors:  Séverine Vermeire; Gert Van Assche; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

8.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

9.  Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study.

Authors:  C E Leijonmarck; P G Persson; G Hellers
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

10.  Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients.

Authors:  R G Farmer; K A Easley; G B Rankin
Journal:  Dig Dis Sci       Date:  1993-06       Impact factor: 3.199

View more
  21 in total

Review 1.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

2.  A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy.

Authors:  Marietta Iacucci; Gilaad G Kaplan; Remo Panaccione; Oluseyi Akinola; Brendan Cord Lethebe; Mark Lowerison; Yvette Leung; Kerri L Novak; Cynthia H Seow; Stefan Urbanski; Parham Minoo; Xianyong Gui; Subrata Ghosh
Journal:  Am J Gastroenterol       Date:  2017-11-14       Impact factor: 10.864

Review 3.  Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature.

Authors:  Umar Darr; Nabeel Khan
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 4.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

Authors:  Mahmoud H Mosli; Claire E Parker; Sigrid A Nelson; Kenneth A Baker; John K MacDonald; G Y Zou; Brian G Feagan; Reena Khanna; Barrett G Levesque; Vipul Jairath
Journal:  Cochrane Database Syst Rev       Date:  2017-05-25

Review 5.  Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?

Authors:  Franco Scaldaferri; Carmen Correale; Antonio Gasbarrini; Silvio Danese
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

6.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes.

Authors:  Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin
Journal:  Clin Gastroenterol Hepatol       Date:  2017-02-24       Impact factor: 11.382

7.  Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It?

Authors:  Edith Y Ho; Fabio Cominelli; Jeffry Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

8.  Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.

Authors:  Talia Zenlea; Eric U Yee; Laura Rosenberg; Marie Boyle; Kavinderjit S Nanda; Jacqueline L Wolf; Kenneth R Falchuk; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

9.  The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine.

Authors:  Giuseppe Frieri; Brigida Galletti; Mirko Di Ruscio; Rachele Tittoni; Annalisa Capannolo; Donatella Serva; Giovanni Latella; Laura Sollima; Pietro Leocata; Stefano Necozione; Rosamarie Frieri; Angelo Viscido
Journal:  Therap Adv Gastroenterol       Date:  2017-08-25       Impact factor: 4.409

10.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.